PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status

Radiotherapy and Oncology

Volumn 86, Issue 3, 2008, Pages 407-411

  Supiot, Stéphane ^a,b   Zhao, Helen ^a   Wiman, Klas ^c   Hill, Richard P ^a   Bristow, Robert G ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hypoxia; p53; PRIMA 1; Prostate cancer; Radiosensitizer

Indexed keywords

HETEROCYCLIC COMPOUND; PRIMA 1; PROTEIN P53; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CLONE; CELL CYCLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION;

EID: 40249104606     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.01.001     Document Type: Article

References (22)

1. E. Deutsch L. Maggiorella P. Eschwege J. Bourhis J.C. Soria B. Abdulkarim Environmental, genetic, and molecular features of prostate cancer Lancet Oncol 5 2004 303 313
2. L. Weisz M. Oren V. Rotter Transcription regulation by mutant p53 Oncogene 26 2007 2202 2211
3. S. Strano S. Dell’Orso S. Di Agostino G. Fontemaggi A. Sacchi G. Blandino Mutant p53: an oncogenic transcription factor Oncogene 26 2007 2212 2219
4. A.R. Cuddihy R.G. Bristow The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 23 2004 237 257
5. V.J. Bykov N. Issaeva A. Shilov Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat Med 8 2002 282 288
6. G. Selivanova K.G. Wiman Reactivation of mutant p53: molecular mechanisms and therapeutic potential Oncogene 26 2007 2243 2254
7. V.J. Bykov N. Zache H. Stridh PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis Oncogene 24 2005 3484 3491
8. G.P. Bromfield A. Meng P. Warde R.G. Bristow Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill Prostate Cancer Prostatic Dis 6 2003 73 85
9. A.X. Meng F. Jalali A. Cuddihy Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells Radiother Oncol 76 2005 168 176
10. S.T. Al Rashid G. Dellaire A. Cuddihy Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo Cancer Res 65 2005 10810 10821
11. S. Supiot S. Gouard J. Charrier Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines Clin Cancer Res 11 2005 7047s 7052s
12. S. Supiot F. Thillays E. Rio Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation Radiother Oncol 83 2007 97 101
13. A. Choudhury A. Cuddihy R.G. Bristow Radiation and new molecular agents part I: targeting ATM–ATR checkpoints, DNA repair, and the proteasome Semin Radiat Oncol 16 2006 51 58
14. V.J. Bykov N. Issaeva G. Selivanova K.G. Wiman Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the national cancer institute database Carcinogenesis 23 2002 2011 2018
15. H. Nahi S. Lehmann L. Mollgard Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion Br J Haematol 127 2004 285 291
16. H. Nahi M. Merup S. Lehmann PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion Br J Haematol 132 2006 230 236
17. A.H. Cory J. Chen J.G. Cory Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis Anticancer Res 26 2006 1289 1295
18. J. Wischhusen U. Naumann H. Ohgaki F. Rastinejad M. Weller CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death Oncogene 22 2003 8233 8245
19. N. Chan M. Milosevic R.G. Bristow Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies Future Oncol 3 2007 329 341
20. R.G. Bristow H. Ozcelik F. Jalali N. Chan D. Vesprini Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies Radiother Oncol 83 2007 200 230
21. M. Nordsmark J.G. Eriksen V. Gebski J. Alsner M.R. Horsman J. Overgaard Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients Radiother Oncol 83 2007 389 397
22. 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer Radiother Oncol 83 2007 406 410